Table 1.
PI3K exon 20 mutations and clinical outcomes of panitumumab-or cetuximab-based treatment in wild-type KRAS patients with metastatic colorectal cancer
| References | Year | Regimen | Design | Mutant/wild-type | OS | PFS | OR (%) |
|---|---|---|---|---|---|---|---|
| Moroni et al61 | 2005 | CTX/Pani ± chemotherapy | RCo | 2/21 | NA | NA | NA |
| Perron et al33 | 2009 | CTX/Pani ± chemotherapy | RCo | 1/17 | NA | NA | NA |
| De Roock et al29 | 2010 | CTX/Pani ± chemotherapy | RCo | 9/329 | 34 vs 51 w HR=3.29 P=0.0057 |
11.5 vs 24 w HR=2.52 P=0.013 |
0% vs 36.8% OR=0.00 P=0.029 |
Abbreviations: CTX, cetuximab; Pani, panitumumab; RCo, retrospective cohort study; NA, date not available; PFS, progression-free survival; OS, overall survival; w, weeks; OR, odds ratio; HR, hazard ratio.